Recent Updates — AEMD

Aethlon Medical, Inc. entered into a definitive merger agreement with North Immunology, Inc., an all-stock transaction where North Immunology will become a wholly owned subsidiary before merging into Aethlon's surviving entity. The combined company will operate as North Immunology, Inc., trading on Nasdaq under the ticker NRTX, with pre-merger North Immunology stockholders expected to own approximately 95.25% of the new entity and Aethlon shareholders retaining about 4.75%. Concurrently, a $180 million oversubscribed private placement (PIPE) is closing immediately prior to the merger, consisting of $146 million in cash and $34 million from convertible notes, providing capital through the second half of 2028. Aethlon shareholders will receive one contingent value right per share, entitling them to proceeds from any future monetization of Aethlon's legacy Hemopurifier assets. The transaction is expected to close in Q1 2027, subject to stockholder and regulatory approvals. Aethlon Medical operates as a medical therapeutic company developing immunotherapeutic devices for cancer and viral diseases.

Aethlon Medical reported fiscal first quarter results for the period ended June 30, 2026. The company raised approximately $4.0 million in gross proceeds through a public offering of common stock subsequent to the quarter-end. Cash and cash equivalents stood at approximately $4.9 million as of June 30, 2026. Operating expenses decreased 11.9% to approximately $1.6 million compared to $1.8 million in the prior-year period. Clinically, the company dosed the first participant in the third and final cohort of its Phase 1 oncology study in Australia and had a Long COVID manuscript accepted for publication. Aethlon Medical is a clinical-stage medical therapeutic company developing the Hemopurifier, an investigational extracorporeal immunotherapeutic platform designed to remove tumor-derived extracellular vesicles and enveloped viruses from circulation.

Aethlon Medical, Inc. filed a Certificate of Change with the Nevada Secretary of State on July 30, 2026, authorizing a one-for-five reverse stock split of its common stock. The transaction becomes effective at 10:00 a.m. Eastern Time on July 31, 2026, with split-adjusted trading expected to commence on August 4, 2026. The company stated the move supports capital markets strategy and compliance with Nasdaq Listing Rule 5550(a)(2). Authorized shares will decrease from 100 million to 20 million, reducing outstanding shares from approximately 3.25 million to roughly 649,914. Fractional shares are rounded up to whole shares rather than paid out in cash. Aethlon Medical, Inc. operates in the medical device industry, specializing in extracorporeal blood purification technologies.

Aethlon Medical, Inc. entered into a Securities Purchase Agreement on July 6, 2026, to conduct a registered public offering. The company issued 263,000 shares of common stock, 5,633,009 common warrants, and 5,370,009 pre-funded warrants at a combined price of $0.71 per unit. The offering closed on July 7, 2026, generating approximately $4.0 million in gross proceeds and approximately $3.335 million in net proceeds after paying Maxim Group LLC a 6.25% cash fee and expense reimbursements. Net proceeds are intended for general working capital. Aethlon Medical, Inc. is a medical technology company.